Thus, in ordinary clinical practice based on the guidelines for the prevention and treatment of anti‐EGFR ab‐related dermatologic toxicities,30 the alleviation of grade 3 skin toxicity reactions by prophylactic management might result in no impairment of either HRQOL or skin‐related QOL. This evidence concerns the gene EGFR and neoplasm.